Kintor Pharma-B (09939) saw its shares rise more than 5% during morning trading. At the time of writing, the stock was up 5.54%, trading at HK$4.38, with a turnover of HK$1.9909 million. The increase follows an announcement by Kintor Pharma that its wholly-owned subsidiary has entered into an exclusive strategic cooperation framework agreement with CHICMAX (02145) in the cosmetics sector. The two companies will collaborate deeply on Kintor's cosmetic ingredient KT-939, which is designed for skin brightening and spot reduction. They plan to jointly advance the registration of the ingredient and related products, accelerating its commercialization. The partnership aims to develop what they describe as the "most powerful domestic whitening agent" with significant industry influence.